RecruitingRecruiting
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
NCT05268692 · Kochi University
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Neoadjuvant Chemotherapy for Pancreatic Cancer; GS vs. GnP
About this study
gemcitabine plus S-1 versus gemcitabine plus nab-paclitaxel
Eligibility criteria
Inclusion Criteria:
elective pancreatectomy for pancreatic cancer
Exclusion Criteria:
a previous cancer surgery a body weight loss of \>10% during the 6 months before surgery the presence of distant metastases seriously impaired function of vital organs because of respiratory, renal, or heart disease.
Study design
Enrollment target: 500 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2019-01-01
Estimated completion: 2030-12-31
Last updated: 2022-03-07
Interventions
Drug: GSDrug: GnP
Primary outcomes
- • overall survival (5 years)
Sponsor
Kochi University · other
All locations (1)
Takehiro OkabayashiRecruiting
Kochi, Japan